Biotech Values

[jbog]

Hattie,

I would think that the FDA doesn't look to kindly to Momenta's IP when trying to protect others from entering the generic field. In many ways I'd say that the FDA will do everything possible to circumvent Momenta.

The main thrust in bio-generics is not to only allow one generic competitor for each drug.